Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats

Emerging evidence supports a key role for the gut microbiota in metabolic diseases, including type 2 diabetes (T2D) and obesity. The dipeptidyl peptidase-4 inhibitor vildagliptin is highly efficacious in treating T2D. However, whether vildagliptin can alter the gut microbiome is still unclear. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qian, Xiao, Xinhua, Li, Ming, Yu, Miao, Ping, Fan, Zheng, Jia, Wang, Tong, Wang, Xiaojing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643055/
https://www.ncbi.nlm.nih.gov/pubmed/29036231
http://dx.doi.org/10.1371/journal.pone.0184735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643055/
https://www.ncbi.nlm.nih.gov/pubmed/29036231
http://dx.doi.org/10.1371/journal.pone.0184735

Ejemplares similares